Xeris Biopharma (XERS) Q4 2025 earnings review
Transition to Profitability Complete, But Heavy 2026 Investments Loom
Xeris closed out a transformational 2025 by delivering its second consecutive quarter of GAAP profitability, driven by a 43% YoY surge in total revenue to a record $85.8M. The company's financial turnaround is reversing years of cash burn, anchored entirely by the explosive adoption of Recorlev, which doubled its sales YoY. However, management's aggressive 2026 guidance—forecasting a massive $70M combined increase in SG&A and R&D expenses—signals a heavily investment-driven year ahead. While top-line momentum is accelerating, the shifting product mix (Gvoke is decelerating) and sheer scale of the upcoming spend will aggressively test the company's newfound operating leverage.
🐂 Bull Case
Recorlev sales accelerated dramatically, reaching $45.3M in Q4 (+100% YoY). It has rapidly become the dominant growth engine, now accounting for 54% of net product revenue, up from 40% a year ago.
Cash and equivalents grew from $71.6M at the end of 2024 to $111.0M at the end of 2025 without dilutive financing, proving the core business generates enough cash to fund its own pipeline.
🐻 Bear Case
Guidance implies a ~$70M combined increase in SG&A and R&D for 2026. With revenue guided to increase by ~$90M at the midpoint, the vast majority of incremental gross profit will be consumed by operating expenses, muting EPS expansion.
Gvoke growth decelerated sharply to just 5.9% YoY in Q4 (down from 26% in Q1). If the legacy portfolio stagnates, the pressure on Recorlev to support the entire expense structure intensifies.
⚖️ Verdict: ⚪
Neutral/Cautiously Optimistic. The achievement of structural profitability is a massive milestone. However, the aggressive step-up in 2026 expenses and the noticeable deceleration in Gvoke introduce significant execution risk that investors must weigh against Recorlev's undeniable momentum.
Key Themes
Recorlev is the Undisputed Growth Engine
Recorlev revenue grew an accelerating 100.5% YoY to $45.3M in Q4, driven by compounding patient demand. The product is single-handedly pulling the company into profitability and absorbing the weight of the broader enterprise. Management's 2026 guidance relies heavily on this asset continuing its steep adoption curve.
Operating Expense Surge for 2026
Management laid out an aggressive spending plan for 2026: SG&A will increase by ~$45M (to ~$227M) to fund Recorlev commercial expansion, and R&D will jump by ~$25M (to ~$56M) for the XP-8121 Phase 3 trial. This combined $70M increase is massive compared to the company's $292M FY25 revenue base, presenting a tangible risk to bottom-line margin expansion if revenue targets fall short.
Gvoke Growth is Decelerating Rapidly
A clear negative trend has emerged for Gvoke. YoY growth has decelerated sequentially all year: 25.7% (Q1) -> 17.1% (Q2) -> 9.6% (Q3) -> 5.9% (Q4). Furthermore, management attributed Q4's meager 6% growth to 'favorable net pricing,' conspicuously omitting mention of prescription volume growth, suggesting volume may have plateaued.
Surprising Keveyis Reversal
After suffering YoY revenue declines for the first three quarters of 2025 (-12.7%, -12.5%, -2.1%), Keveyis demonstrated a reversing trend, jumping 15.1% YoY in Q4 to $12.8M. Management cited 'increased patient demand,' suggesting the legacy asset might still have durable cash-generating power.
Phase 3 Pipeline Catalyst: XP-8121
The $25M step-up in 2026 R&D is entirely dedicated to XP-8121, a once-weekly subcutaneous injection for hypothyroidism. As this moves into Phase 3, it transforms Xeris from a single-catalyst commercial story into a clinical-stage development play with a potentially massive total addressable market.
Other KPIs
Accelerating dramatically from $8.3M in the prior year period. For the full year, Adjusted EBITDA was $59.4M, a massive $58.2M improvement over 2024. This proves out the operating leverage model before the heavy 2026 reinvestment cycle begins.
Stable and highly favorable. Cost of Goods Sold increased by only $5.7M (16%) for the full year, while Net Product Revenue surged $86.3M (44%). The shift in product mix toward the higher-margin Recorlev is creating excellent unit economics.
Accelerating balance sheet strength. Cash grew from $71.6M at the end of 2024 to $111.0M without tapping the equity markets. Trade accounts receivable also grew proportionally to $51.0M, indicating healthy, collection-backed sales growth.
Guidance
Accelerating nominally, but slightly decelerating in percentage terms. The midpoint of $382.5M implies ~31% YoY growth, compared to the 43.7% growth achieved in FY25. This assumes Recorlev carries the vast majority of the incremental $90.5M in new sales.
Accelerating aggressively. This represents a roughly 25% increase over the $182.3M spent in 2025, dedicated to Recorlev commercialization. It is a stark departure from 2025, where SG&A grew only 12% YoY.
Accelerating sharply. Represents an ~80% increase over the $31.1M spent in 2025, marking the commencement of heavy clinical trial spending for the XP-8121 Phase 3 program.
Stable positive outlook. Despite the $70M planned jump in operating expenses, management expects gross profit dollars from the $90M+ revenue growth to outpace the spend, resulting in a net increase in full-year Adjusted EBITDA.
Key Questions
Gvoke Deceleration Dynamics
Gvoke growth slowed to just 5.9% in Q4, and the release cited 'favorable net pricing' rather than volume. Has prescription volume growth plateaued, and what is the assumption for Gvoke in the 2026 guidance?
SG&A Allocation Details
With an aggressive $45M planned step-up in SG&A, how much of this is structural headcount for Recorlev sales reps versus variable marketing/direct-to-consumer spend that can be dialed back if top-line growth misses targets?
Keveyis Q4 Reversal
Keveyis reversed a trend of YoY declines with a 15% jump in Q4. Was this due to a one-time inventory stocking event, or is there a structural re-acceleration in patient demand for this mature asset?
XP-8121 Phase 3 Cadence
Regarding the $25M increase in R&D, how will this spend be weighted throughout 2026? Will the bulk of it hit in the second half of the year as patients are actively dosed?